Immunotherapy for the rheumatoid arthritis-associated coronary artery disease: promise and future.
CONCLUSIONS: RA is an independent risk factor for CAD, which mainly results from the underlying inflammatory cascade; therefore, anti-inflammatory therapy, especially the emerging novel biologic drugs, is important for CAD management in patients with RA and may also be a promising approach among the general population.
PMID: 31855971 [PubMed - as supplied by publisher]
Source: Chinese Medical Journal - Category: General Medicine Authors: Wang L, Zhang Y, Zhang SY Tags: Chin Med J (Engl) Source Type: research
More News: Arthritis | Cardiology | Cardiovascular | China Health | Clinical Trials | General Medicine | Heart | Immunotherapy | Rheumatoid Arthritis | Rheumatology | Study